Long‐term L‐Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double‐blind, cross‐over, placebo‐controlled intervention study

Abstract

This study does not support the hypothesis that oral T3 treatment might be beneficial to patients with chronic, stable systolic HF with a modest degree of reduced LVEF and low-normal serum T3 concentrations. The study included both functional studies of heart contractility as well as measures of the neurohormonal activation.